Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.
|
Nature
|
2007
|
17.68
|
2
|
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
|
Cancer Cell
|
2002
|
11.83
|
3
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
4
|
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
|
Nature
|
2008
|
10.12
|
5
|
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
|
N Engl J Med
|
2009
|
7.95
|
6
|
Acute lymphoblastic leukemia.
|
N Engl J Med
|
2004
|
7.83
|
7
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
8
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
9
|
Implementing genomic medicine in the clinic: the future is here.
|
Genet Med
|
2013
|
4.89
|
10
|
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
|
Blood
|
2004
|
4.21
|
11
|
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
|
N Engl J Med
|
2004
|
4.16
|
12
|
Germline genomic variants associated with childhood acute lymphoblastic leukemia.
|
Nat Genet
|
2009
|
3.71
|
13
|
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia.
|
N Engl J Med
|
2003
|
3.57
|
14
|
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2011
|
3.40
|
15
|
Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
|
J Clin Oncol
|
2011
|
3.05
|
16
|
Moving towards individualized medicine with pharmacogenomics.
|
Nature
|
2004
|
2.99
|
17
|
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
|
Blood
|
2012
|
2.82
|
18
|
Results of therapy for acute lymphoblastic leukemia in black and white children.
|
JAMA
|
2003
|
2.77
|
19
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
20
|
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.
|
Lancet Oncol
|
2010
|
2.52
|
21
|
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
|
Genome Res
|
2011
|
2.52
|
22
|
Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected].
|
J Clin Oncol
|
2008
|
2.51
|
23
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
|
Clin Pharmacol Ther
|
2013
|
2.39
|
24
|
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia.
|
JAMA
|
2007
|
2.38
|
25
|
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
|
Blood
|
2010
|
2.37
|
26
|
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
|
J Clin Oncol
|
2008
|
2.29
|
27
|
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
|
J Clin Oncol
|
2009
|
2.20
|
28
|
Pharmacogenomics: challenges and opportunities.
|
Ann Intern Med
|
2006
|
1.96
|
29
|
Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes.
|
Nat Genet
|
2005
|
1.94
|
30
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
31
|
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.
|
Blood
|
2008
|
1.89
|
32
|
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.88
|
33
|
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.
|
Curr Drug Metab
|
2014
|
1.88
|
34
|
Development and implementation of a pharmacist-managed clinical pharmacogenetics service.
|
Am J Health Syst Pharm
|
2011
|
1.85
|
35
|
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
|
J Natl Cancer Inst
|
2013
|
1.81
|
36
|
Development and use of active clinical decision support for preemptive pharmacogenomics.
|
J Am Med Inform Assoc
|
2013
|
1.80
|
37
|
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
|
Blood
|
2014
|
1.80
|
38
|
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells.
|
Nat Genet
|
2003
|
1.79
|
39
|
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
|
Blood
|
2008
|
1.79
|
40
|
Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.
|
J Clin Oncol
|
2003
|
1.75
|
41
|
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
|
J Clin Oncol
|
2013
|
1.75
|
42
|
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.
|
Blood
|
2011
|
1.67
|
43
|
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.
|
Hum Mol Genet
|
2012
|
1.66
|
44
|
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
|
J Clin Oncol
|
2011
|
1.60
|
45
|
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
|
Cancer Cell
|
2005
|
1.58
|
46
|
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
|
Annu Rev Pharmacol Toxicol
|
2014
|
1.58
|
47
|
Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.
|
Pediatr Blood Cancer
|
2010
|
1.54
|
48
|
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2005
|
1.53
|
49
|
Thiopurine methyltransferase in acute lymphoblastic leukemia.
|
Blood
|
2006
|
1.52
|
50
|
Ancestry and pharmacogenetics of antileukemic drug toxicity.
|
Blood
|
2007
|
1.52
|
51
|
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group.
|
J Clin Oncol
|
2012
|
1.52
|
52
|
PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.
|
Am J Med Genet C Semin Med Genet
|
2014
|
1.49
|
53
|
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.46
|
54
|
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
|
J Clin Invest
|
2005
|
1.46
|
55
|
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
|
Nat Genet
|
2013
|
1.45
|
56
|
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.
|
Blood
|
2005
|
1.42
|
57
|
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
|
Cancer
|
2008
|
1.42
|
58
|
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2012
|
1.39
|
59
|
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
|
PLoS Med
|
2008
|
1.37
|
60
|
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.
|
Nat Med
|
2011
|
1.34
|
61
|
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
|
J Clin Oncol
|
2014
|
1.31
|
62
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
J Natl Cancer Inst
|
2010
|
1.30
|
63
|
Genome-wide association studies in pharmacogenomics: successes and lessons.
|
Pharmacogenet Genomics
|
2013
|
1.30
|
64
|
PharmGKB summary: methotrexate pathway.
|
Pharmacogenet Genomics
|
2011
|
1.27
|
65
|
A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday.
|
J Orthop Res
|
2009
|
1.25
|
66
|
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2008
|
1.18
|
67
|
Genome-wide study of methotrexate clearance replicates SLCO1B1.
|
Blood
|
2012
|
1.17
|
68
|
Improved prognosis for older adolescents with acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
1.16
|
69
|
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
|
Clin Cancer Res
|
2012
|
1.15
|
70
|
Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.
|
Drug Metab Dispos
|
2008
|
1.12
|
71
|
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.
|
Blood
|
2003
|
1.10
|
72
|
Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
|
J Clin Oncol
|
2014
|
1.10
|
73
|
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.
|
Blood
|
2006
|
1.10
|
74
|
De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
|
Blood
|
2002
|
1.08
|
75
|
Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
|
PLoS Comput Biol
|
2010
|
1.07
|
76
|
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2008
|
1.05
|
77
|
The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
|
J Natl Cancer Inst
|
2008
|
1.04
|
78
|
Nomenclature for alleles of the thiopurine methyltransferase gene.
|
Pharmacogenet Genomics
|
2013
|
1.03
|
79
|
Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
|
Pharmacogenetics
|
2002
|
1.03
|
80
|
A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.
|
Cancer Chemother Pharmacol
|
2002
|
1.02
|
81
|
Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression.
|
Hum Mol Genet
|
2007
|
1.01
|
82
|
HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.
|
Clin Chem
|
2002
|
1.01
|
83
|
Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
|
Cancer
|
2012
|
0.99
|
84
|
Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis.
|
Blood
|
2004
|
0.98
|
85
|
A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.
|
Pharmacogenetics
|
2004
|
0.96
|
86
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
Clin Cancer Res
|
2007
|
0.96
|
87
|
Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.
|
J Clin Oncol
|
2014
|
0.96
|
88
|
CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia.
|
J Clin Oncol
|
2008
|
0.96
|
89
|
Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics.
|
Cancer Res
|
2007
|
0.95
|
90
|
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
|
Cancer
|
2008
|
0.95
|
91
|
Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada.
|
Environ Health Perspect
|
2007
|
0.94
|
92
|
Lymphoid gene expression as a predictor of risk of secondary brain tumors.
|
Genes Chromosomes Cancer
|
2005
|
0.94
|
93
|
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
|
Blood
|
2005
|
0.93
|
94
|
Evidence for age as a modifier of genetic associations for lipid levels.
|
Ann Hum Genet
|
2011
|
0.92
|
95
|
Acute lymphoblastic leukemia.
|
Hematology Am Soc Hematol Educ Program
|
2002
|
0.91
|
96
|
Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing.
|
Int J Data Min Bioinform
|
2011
|
0.91
|
97
|
Thiopurine pathway.
|
Pharmacogenet Genomics
|
2010
|
0.90
|
98
|
High-throughput asparaginase activity assay in serum of children with leukemia.
|
Int J Clin Exp Med
|
2013
|
0.90
|
99
|
Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis.
|
Am J Pathol
|
2013
|
0.89
|
100
|
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
|
Pharmacogenomics
|
2014
|
0.89
|
101
|
Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites.
|
Toxicol Lett
|
2006
|
0.89
|
102
|
A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype.
|
Hum Hered
|
2014
|
0.87
|
103
|
Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.
|
J Pharmacokinet Pharmacodyn
|
2002
|
0.87
|
104
|
Childhood acute lymphoblastic leukemia.
|
Rev Clin Exp Hematol
|
2002
|
0.86
|
105
|
Late-onset delayed excretion of methotrexate.
|
Cancer Chemother Pharmacol
|
2004
|
0.86
|
106
|
Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.
|
Clin Cancer Res
|
2002
|
0.86
|
107
|
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
|
Drug Metab Dispos
|
2004
|
0.86
|
108
|
Substrain-specific differences in survival and osteonecrosis incidence in a mouse model.
|
Comp Med
|
2012
|
0.85
|
109
|
Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells.
|
Am J Hum Genet
|
2006
|
0.85
|
110
|
Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia.
|
Best Pract Res Clin Haematol
|
2002
|
0.84
|
111
|
Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.
|
PLoS One
|
2012
|
0.84
|
112
|
Global gene expression as a function of germline genetic variation.
|
Hum Mol Genet
|
2005
|
0.83
|
113
|
Etoposide induces chimeric Mll gene fusions.
|
FASEB J
|
2003
|
0.82
|
114
|
Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
|
J Clin Oncol
|
2003
|
0.82
|
115
|
Etoposide pathway.
|
Pharmacogenet Genomics
|
2009
|
0.82
|
116
|
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.
|
Cancer
|
2013
|
0.82
|
117
|
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.
|
Cancer Chemother Pharmacol
|
2013
|
0.82
|
118
|
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2011
|
0.81
|
119
|
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.
|
Pharmacogenet Genomics
|
2008
|
0.81
|
120
|
Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs.
|
PLoS One
|
2008
|
0.80
|
121
|
Polymorphisms in the MLL breakpoint cluster region (BCR).
|
Hum Genet
|
2003
|
0.80
|
122
|
The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011.
|
Pediatr Blood Cancer
|
2012
|
0.79
|
123
|
Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
|
Clin Pharmacol Ther
|
2003
|
0.79
|
124
|
Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?
|
Nat Clin Pract Oncol
|
2008
|
0.78
|
125
|
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.
|
Pharmacogenet Genomics
|
2006
|
0.77
|
126
|
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.
|
Circ Cardiovasc Genet
|
2016
|
0.77
|
127
|
Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate.
|
J Pediatr Hematol Oncol
|
2016
|
0.76
|
128
|
Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?
|
Leuk Lymphoma
|
2006
|
0.76
|
129
|
Can the genotoxicity of chemotherapy be predicted?
|
Lancet
|
2004
|
0.76
|
130
|
Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model.
|
Pharmacogenet Genomics
|
2014
|
0.76
|
131
|
Continue to study childhood ALL.
|
Blood
|
2008
|
0.75
|
132
|
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.
|
Cancer
|
2010
|
0.75
|
133
|
A Semiparametric Bayesian Model for Repeatedly Repeated Binary Outcomes.
|
J R Stat Soc Ser C Appl Stat
|
2008
|
0.75
|
134
|
Genetics of pleiotropic effects of dexamethasone.
|
Pharmacogenet Genomics
|
2017
|
0.75
|